Glenmark Pharmaceuticals Ltd - ESG Rating & Company Profile powered by AI
This page contains a Q&A table about Glenmark Pharmaceuticals Ltd. Check the bottom of the page for potential risks for Glenmark Pharmaceuticals Ltd based on industry, geography and size. The Sustainability assessment for Glenmark Pharmaceuticals Ltd indicates the company's transparency towards the United Nations SDGs.
Glenmark Pharmaceuticals Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.0; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.
8.0
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Glenmark Pharmaceuticals Ltd | 8.0 | High |
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Glenmark Pharmaceuticals Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd report the average age of the workforce?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd offer flexible work?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd conduct supply chain audits?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd disclose water use targets?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Glenmark Pharmaceuticals Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Glenmark Pharmaceuticals Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Glenmark Pharmaceuticals Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd disclose its waste policy?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd disclose energy use targets?
Sign up for free to unlockDoes Glenmark Pharmaceuticals Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Glenmark Pharmaceuticals Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Glenmark Pharmaceuticals Ltd
These potential risks are based on the size, segment and geographies of the company.
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830, an OX40 antagonist monoclonal antibody, which is in Phase 2b clinical trial for the treatment of atopic dermatitis; ISC 17536, an oral transient receptor potential ankyrin-1 antagonist, which has completed Phase 2a clinical trial for the treatment of diabetic peripheral neuropathy; ISB 1302, a HER2 X CD3 beat bispecific antibody, which is in Phase 1/2 clinical trial for the treatment of metastatic HER2-positive breast cancer; and ISB 1342, a CD38 X CD3 beat bispecific antibody that is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma. The company's pre-clinical stage product pipeline comprises ISB 880 for the for the treatment of anti-inflammatory therapy; ISB 1908 and ISB 1909 T-cell engagers for the treatment of oncology; ISB 1442, an innate immune engager for the treatment of oncology; ISC XXXXX, an HPK1 inhibitor for the treatment of oncology; and GRC 39815, an inhibitor of the retinoid-related orphan receptor gamma t for the treatment of chronic obstructive pulmonary disorder. It also offers Ryaltris nasal spray for allergic rhinitis. The company was founded in 1977 and is based in Mumbai, India.